Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Takeda Gmbh patents


Recent patent applications related to Takeda Gmbh. Takeda Gmbh is listed as an Agent/Assignee. Note: Takeda Gmbh may have other listings under different names/spellings. We're not affiliated with Takeda Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | Takeda Gmbh-related inventors


Methods for producing virus for vaccine production

The present disclosure relates to methods of producing enterovirus a, e.g., for vaccine production, that include culturing cells in a fixed bed bioreactor. Further provided herein is an enterovirus a produced by the methods of production disclosed herein, as well as compositions, immunogenic compositions, and vaccines related thereto.. ... Takeda Gmbh

Hand, foot, and mouth vaccines and methods of manufacture and use thereof

. . The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.. . ... Takeda Gmbh

Method for producing pyrrole compound

The present invention provides a production method of a 3-cyanopyrrole compound possibly useful as an intermediate for pharmaceutical products. A production method of compound (ii) including subjecting compound (i) to a reduction reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. ... Takeda Gmbh

Parenteral norovirus vaccine formulations

The present invention relates to single dose parental vaccine compositions comprising mixtures of monovalent norovirus virus-like particles. Methods of conferring protective immunity against norovirus infections in a human subject by administering such compositions are also disclosed.. ... Takeda Gmbh

Pyridazinone compounds and their use as daao inhibitors

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein r1 and r2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. . ... Takeda Gmbh

Heterocyclic compound

. . The present invention relates to a compound which can be useful for the treatment or prevention of spt-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including niemann-pick disease).. . ... Takeda Gmbh

2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor

. . . . The present invention provides a compound having a cholinergic muscarinic m1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for alzheimer's disease, schizophrenia, pain, sleep disorder, parkinson's disease dementia, dementia with lewy bodies and the like. The present invention relates to a compound represented by the formula (i) or a salt thereof: wherein each symbol is as defined in the attached description.. ... Takeda Gmbh

Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.. . ... Takeda Gmbh

Administration of dipeptidyl peptidase inhibitors

. . . . . . Pharmaceutical compositions comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof in combination with metformin and in combination with pioglitazone.. . ... Takeda Gmbh

Hand, foot, and mouth vaccines and methods of manufacture and use thereof

The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof. Thus, there is a need to develop vaccines and immunogenic compositions for treating and/or preventing hand, food, and mouth disease, particularly in children. ... Takeda Gmbh

Novel pharmaceutical uses

. . The invention provides a potassium-competitive acid blocker (p-cab) for use in the treatment, prevention and/or reduction of gastro-esophageal reflux disease (gerd) symptoms in patients who are partial responders to a proton pump inhibitor (ppi). The p-cab may, for example, be selected from 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine (vonoprazan), revaprazan (yh1855), yh4808, rq-4 and cs-526, or a salt thereof.. ... Takeda Gmbh

Rolled collagen carrier

The invention relates to a process for the preparation of a rolled compressed collagen carrier and a process for un-rolling said rolled compressed collagen carrier. Said rolled compressed collagen carrier is ready for use in minimally invasive surgery. ... Takeda Gmbh

Process for producing heterocyclic compound

. . The present invention provides a method of efficiently producing an optically active 6-(3-aminopiperidin-1-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivative. The optically active piperidine-3-carboxamide or a derivative thereof, which is obtained by subjecting 1,4,5,6-tetrahydropyridine-3-carboxamide or a derivative thereof to an asymmetric reduction in the presence of a catalyst, is used as an intermediate.. ... Takeda Gmbh

Monocyclic compound

The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.. . ... Takeda Gmbh

03/15/18 / #20180072795

Uti fusion proteins

. . . . The present invention provides uti fusion proteins, dna sequences for producing the same, and pharmaceutical compositions and methods of using the same.. . ... Takeda Gmbh

03/15/18 / #20180072694

Fused heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (i) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].. ... Takeda Gmbh

03/08/18 / #20180066069

Anti-cd38 antibodies

Isolated antibodies that bind to human cd38 and cynomolgus cd38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.. ... Takeda Gmbh

02/15/18 / #20180044472

Production method for poly(amino acid)

. . . . The present invention relates to a graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof (e.g., a graft copolymer (γ-pga-pae) of poly(γ-glutamic acid) (γ-pga) and phenylalanine ethyl ester (pae)), an ionized graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof, nanoparticles containing the ionized graft copolymer, and a production method thereof. The nanoparticles acquired in this way are useful as an adjuvant for producing a vaccine.. ... Takeda Gmbh

02/08/18 / #20180036244

Suspension or composition containing nano-cocrystal and manufacturing method therefor

. . The present invention provides a method of producing a suspension containing a nano-cocrystal having an average particle size of not more than 300 nm, a polymer having a number average molecular weight of not less than 3,000, a surfactant having a number average molecular weight of less than 3,000 and water, which method including wet grinding a cocrystal, which is constituted of an organic compound and a cocrystal former and is not dissociated by wet grinding, in water containing the polymer and the surfactant.. . ... Takeda Gmbh

01/18/18 / #20180016349

Conjugated anti-cd38 antibodies

. . Isolated antibodies that bind to human cd38 and cynomolgus cd38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.. ... Takeda Gmbh

01/11/18 / #20180009780

Piperidine and azepine derivatives as prokineticin receptor modulators

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof (formula (i)) in which m, x, r1, r2, r3 and r5 are as defined in the specification, processes for their preparation, pharmaceutical compositions n containing them and their use in therapy.. . ... Takeda Gmbh

01/11/18 / #20180009746

Process for producing pyrrole compound

The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (viii), which includes reducing compound (iii) and hydrolyzing the reduced product to give compound (iv), subjecting compound (iv) to a sulfonylation reaction to give compound (vi), and subjecting compound (vi) to an amination reaction.. ... Takeda Gmbh

01/11/18 / #20180008691

Compositions and methods for rapid immunization against dengue virus

Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. ... Takeda Gmbh

01/04/18 / #20180002767

Detection of particle-contained reverse transcriptase activity

. . . . The present invention relates to methods and kits for detecting in a sample the presence of a virus particle or a virus-like particle that has reverse transcriptase activity and methods for preparing a retroviral contaminant-free substance. An aspect of the present invention is a method for detecting the presence of a virus particle in a sample of a virus-like particle (vlp) drug substance comprising a step of performing pcr-based reverse transcriptase (pbrt) on a sample of the vlp drug substance that has been treated with a protease.. ... Takeda Gmbh

12/28/17 / #20170369492

1,3-substituted 2-amino-indole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity, and inflammatory bowel disease

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein q, x4, x5, x6, x7, r1, r2, r3 and r8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.. . ... Takeda Gmbh

12/07/17 / #20170349605

Condensed heterocyclic compound

. . . . The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (i) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].. ... Takeda Gmbh

11/30/17 / #20170340621

Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof (formula (i)) in which m, n, w, x, y, z, r1, r2, r3, r4 and r5 are as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease.. . ... Takeda Gmbh

09/07/17 / #20170252436

Liquid formulation comprising gm-csf neutralizing compound

. . . . . . . . . . . . . . . . The present invention relates to aqueous formulations comprising a compound neutralizing gm-csf in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing gm-csf in view of long-term storage. ... Takeda Gmbh

08/17/17 / #20170233700

Method for proliferation of pancreatic progenitor cells

. . The present invention relates to a method for preparing highly pure pancreatic progenitor cells by using pluripotent stem cells such as es cells or ips cells as a source, inducing their differentiation into pancreatic progenitor cells, and culturing and proliferating the pancreatic progenitor cells. Specifically, the present invention relates to a method for proliferation of pancreatic progenitor cells, comprising the step of culturing the pancreatic progenitor cells in a medium containing (i) an egf signal transduction activator and/or an fgf signal transduction activator and (ii) a rock inhibitor.. ... Takeda Gmbh

08/17/17 / #20170233406

Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide

Disclosed is a crystalline polymorph 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide, form g, and processes for making the same. . ... Takeda Gmbh

07/27/17 / #20170210753

Production method of thienopyrimidine derivative

. . . . . . The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (gnrh) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1h,3h)-dione or salt thereof, 1,1′-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.. ... Takeda Gmbh

07/20/17 / #20170202777

Solid preparation

The present invention provides a solid preparation wherein variation in weight is suppressed, a solid preparation wherein the active ingredient is stabilized, and a stabilization method thereof. A solid preparation containing (1) an active ingredient, (2) d-mannitol and (3) an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate. ... Takeda Gmbh

07/06/17 / #20170189943

Antibacterial water

. . . . A novel technique is provided for preserving a liquid pharmaceutical preparation safely and stably. The nano-bubble water of the present invention, which is produced in the presence of a surfactant, a hydrophilic resin and/or an electrolyte and contains not less than 2.0×108 bubbles/ml of nano-bubbles, shows a superior antibacterial action, and can be used as a base of a liquid pharmaceutical preparation showing safe and stable preservation property.. ... Takeda Gmbh

06/29/17 / #20170183326

Cocrystal, production method thereof, and medicament containing cocrystal

The present invention provides a cocrystal of (s)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1h-1,2,4-triazol-5(4h)-one and an organic acid capable of forming a cocrystal with the compound.. . ... Takeda Gmbh

06/22/17 / #20170173007

Pyridazinone compounds and their use as daao inhibitors

. . The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein r1 and r2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. . ... Takeda Gmbh

06/15/17 / #20170166553

Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, in which r1, r2, r3, r4 and r5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. . ... Takeda Gmbh

06/15/17 / #20170165204

Sustained-release composition and method for producing the same

Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.. . ... Takeda Gmbh

06/08/17 / #20170158700

3-substituted 2-amino-indole derivatives

The present invention provides compounds of formula (i) (formula (i)) and pharmaceutically acceptable salts thereof, wherein q, x % x4, x5 x6, x7, r1, r2, r3 and r8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.. . ... Takeda Gmbh

05/18/17 / #20170137880

Method for treating depression and major depressive disorder

The present invention provides methods for treating depression such as major depressive disorder (mdd) in an individual. The invention further provides methods for determining if an individual suffering from depression is likely to respond favorably or experience an enhanced treatment effect in response to treatment with vortioxetine. ... Takeda Gmbh

04/27/17 / #20170114042

Radiolabeled compounds

. . . . . . . . . . The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of ch24h in mammals. The compound of the present invention is represented by the formula (i): wherein each symbol is as defined in the specification.. ... Takeda Gmbh

04/20/17 / #20170107240

Amide compound

The present invention relates to compound (i) or a salt thereof which has a rorγt inhibitory action. In the formula (i), each symbol is as defined in the specification.. ... Takeda Gmbh

04/20/17 / #20170107226

Dihydroxy aromatic heterocyclic compound

Provided is a compound having a d-amino acid oxidase (daao) inhibitory action, and useful as, for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. The present inventors have studied a compound that inhibits daao, and confirm that a dihydroxy aromatic heterocyclic compound has a daao inhibitory action, and completed the present invention. ... Takeda Gmbh

04/13/17 / #20170100474

Methods and compositions for live attenuated viruses

. . Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. ... Takeda Gmbh

03/30/17 / #20170087138

Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

. . . . Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and therapeutically acceptable salts thereof are provide.. . ... Takeda Gmbh

03/23/17 / #20170079915

Solid dispersion

. . . . A solid dispersion for achieving improved solubility and absorbability of a pharmaceutically active ingredient, which contains (1) an amorphous pharmaceutically active ingredient, (2) one or more substances selected from among methyl cellulose and organic acids and (3) an enteric base material. In cases where methyl cellulose is contained therein, the solid dispersion does not contain any water-soluble polymer other than methyl cellulose.. ... Takeda Gmbh

03/16/17 / #20170073340

Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, formula (i) wherein l, x, ra, rb, r1, r2 and r3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. . ... Takeda Gmbh

03/09/17 / #20170066744

1,2-substituted cyclopentanes as orexin receptor antagonists

. . The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, (i) wherein l, x, ra, rb, r1, r2 and r3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. . ... Takeda Gmbh

03/09/17 / #20170065553

Orally dispersible tablet

The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. ... Takeda Gmbh

02/23/17 / #20170049874

Compositions, methods and uses for dengue virus serotype-4 constructs

. . Embodiments herein report compositions, methods and uses for dengue-4 (denv-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, denv-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. ... Takeda Gmbh

02/16/17 / #20170044143

Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease

. . The present invention provides a compound having a cholinergic muscarinic m1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of alzheimer's disease, schizophrenia, pain, sleep disorder, parkinson's disease dementia, dementia with lewy bodies, and the like. The present invention relates to a compound represented by the formula (i) or a salt thereof. ... Takeda Gmbh

02/02/17 / #20170029417

Cyclopropanamine compound and use thereof

. . . . . . The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, rett syndrome, down's syndrome, kabuki syndrome, fragile x syndrome, kleefstra syndrome, neurofibromatosis type 1, noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., alzheimer's disease, parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and huntington's disease), epilepsy (e.g., dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.. ... Takeda Gmbh

01/26/17 / #20170020841

Pharmaceutical preparation containing copolyvidone

. . A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.. . ... Takeda Gmbh

01/19/17 / #20170014347

Dry coated tablet

. . . . . . . . Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.. ... Takeda Gmbh

01/12/17 / #20170008885

Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors

. . The present invention provides a heterocyclic compound having a tlr7, tlr9, tlr7/8, tlr7/9 or tlr7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.. ... Takeda Gmbh

01/12/17 / #20170007607

Solid preparation

The present invention provides a solid preparation excellent in disintegration property and preservation stability. The present invention relates to a solid preparation containing (1) 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (a)) or a salt thereof, (2) a saccharide, and (3) sodium stearyl fumarate. ... Takeda Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Takeda Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Takeda Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###